The European Commission has approved Novartis’ Farydak (panobinostat) capsules, in combination with bortezomib and dexamethasone, for treating adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory agent (IMiD).

Farydak in combination with bortezomib and dexamethasone is also approved in the US, Chile, and Japan for certain patients with previously treated multiple myeloma. The exact indication for Farydak varies by country. In the US, Farydak is approved in combination with bortezomib and dexamethasone for treating multiple myeloma in patients who have received at least two prior regimens, including bortezomib and an IMiD.

Farydak is an histone deacetylase inhibitor with epigenetic activity, marking a new mechanism for treating multiple myeloma.

Source: Novartis